8-K: Vaxart Halts BARDA-Funded COVID-19 Vaccine Work

Vaxart, Inc. received a stop work order from Advanced Technology International, halting most efforts on its BARDA-funded oral COVID-19 vaccine trial.

Summary

• Vaxart, Inc. received a stop work order on August 5, 2025, from Advanced Technology International (ATI) concerning Project Agreement No. 01; RRPV-24-04-NGVx-003.
• This project, funded by the Biomedical Advanced Research and Development Authority (BARDA), was for the company's oral pill COVID-19 vaccine candidate.
• The company is permitted to continue per protocol follow-up for the 10,000-person cohort already dosed in the Phase 2b comparative study.
• Approximately half of the targeted participants for the trial have been enrolled.
• No reason for the stop work order has been provided, but a follow-up notice is expected.
• The independent Data Safety Monitoring Board (DSMB) had determined on July 14, 2025, that the study could proceed without modification regarding safety.

Sentiment

Score: 2

Explanation: The stop work order on a major government-funded project is a significant negative event, indicating a substantial setback for the company's primary vaccine candidate. While safety was cleared, the project's future is highly uncertain, impacting financial stability and development timelines.

Positives

• The independent Data Safety Monitoring Board (DSMB) determined on July 14, 2025, that the Phase 2b comparative study could continue without modification, indicating no immediate safety concerns.
• The company is permitted to continue per protocol follow-up for the 10,000-person cohort already dosed in the trial.

Negatives

• Receipt of a stop work order from Advanced Technology International (ATI) for a significant BARDA-funded project.
• The stop work order halts most efforts on the oral pill COVID-19 vaccine candidate trial.
• No reason for the stop work order was provided, creating uncertainty.
• Potential loss of future funding under the Project Agreement.

Risks

• Uncertainty regarding the reason for the stop work order and potential future actions by ATI, BARDA, or the U.S. government, including termination of the Project Agreement.
• Risk to the company's ability to achieve milestones and deliverables under the Project Agreement.
• Risks associated with the company's continuing operating losses.
• General risks detailed in the company's most recent Annual Report on Form 10-K and other SEC filings.

Future Outlook

Forward-looking statements indicate uncertainty regarding the company's receipt of additional funding under the Project Agreement and potential actions by ATI, BARDA, or other U.S. government entities, including termination of the work. The company cautions that actual results could differ materially due to risks such as achieving milestones and managing operating losses.

Management Comments

• The Company has, to date, not been provided with any further details, including the reason for such stop work order.
• The Notice indicated that a follow-up notice with further details will follow.

Industry Context

This event highlights the inherent risks in government-funded research and development contracts within the biotechnology and pharmaceutical sectors, particularly for vaccine candidates. Such contracts are often subject to evolving public health priorities, funding reallocations, and ongoing scientific evaluations, which can lead to abrupt changes like stop work orders, impacting companies heavily reliant on such funding.

Stakeholder Impact

• Shareholders: Likely negative impact due to uncertainty surrounding the key vaccine program and potential loss of funding, which could affect stock price.
• Employees: Potential impact on job security or project assignments related to the halted work.
• Customers (future vaccine recipients): Delays or termination of the oral vaccine program could impact the availability of this specific vaccine option.
• Creditors: Increased financial risk due to potential loss of revenue or funding.

Next Steps

• Await a follow-up notice from Advanced Technology International (ATI) with further details regarding the stop work order.
• Continue per protocol follow-up for the 10,000-person cohort already dosed in the Phase 2b comparative study.

Key Dates

Recommendation

The stop work order on a critical, government-funded clinical trial represents a severe setback for Vaxart. This event introduces significant uncertainty regarding the future of their lead oral COVID-19 vaccine candidate and its associated funding. While the DSMB cleared safety, the lack of a stated reason for the halt suggests potential issues beyond safety, or a strategic shift by the funding agency. This materially impacts the company's development pipeline, revenue prospects, and overall valuation, warranting a sell recommendation given the immediate and profound negative implications.

Keywords

Vaxart, VXRT, BARDA, COVID-19 vaccine, oral vaccine, stop work order, clinical trial, biotechnology, pharmaceuticals, Phase 2b, government contract